{"id":2824,"date":"2020-09-24T05:30:00","date_gmt":"2020-09-24T05:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-perfusions-warrant-program-2020-2022\/"},"modified":"2020-09-24T05:30:00","modified_gmt":"2020-09-24T05:30:00","slug":"xvivo-perfusions-warrant-program-2020-2022","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusions-warrant-program-2020-2022\/","title":{"rendered":"XVIVO Perfusion\u2019s warrant program 2020\/2022"},"content":{"rendered":"
\n

On 31 March 2020, the annual general meeting of XVIVO Perfusion AB (publ) (\u201cXVIVO\u201d) resolved to issue up to 408,000 warrants of series 2020\/2022 to employees of XVIVO and XVIVO\u2019s Swedish subsidiaries. The application period to subscribe for warrants ended on September 23, 2020 and a total of 374,000 warrants were subscribed for.<\/strong><\/p>\n<\/div>\n

\n

Employees who have subscribed for warrants have paid an option premium corresponding to the market value calculated in accordance with the Black & Scholes valuation model. Each warrant entitles to subscription for one new share in XVIVO during the period 2\u00a0May\u201331\u00a0May 2022 for a subscription price of SEK 205.88, which corresponds to 150 percent of the volume weighted average price for XVIVO\u2019s shares listed on Nasdaq Stockholm for each trading day during the period 4\u00a0May\u201315 May 2020. The application period to subscribe for warrants ended on 23 September 2020 and a total of 374,000 warrants were subscribed for. The last subscriptions were made on June 2, 2020.
\u00a0
If all warrants are exercised, XVIVO\u2019s share capital will increase by approximately SEK 9,559 corresponding to a dilution of approximately 1.4 percent of the total number of shares and votes in XVIVO.
\u00a0
Gothenburg, 24 September 2020
XVIVO Perfusion AB (publ)<\/p>\n<\/div>\n

\n

For further information please contact:<\/strong><\/p>\n\n

Dag Andersson, CEO, +46 76 643 30 31, e-post: dag.andersson@xvivoperfusion.com<\/a>
Christoffer Rosenblad, CFO, +46 73 519 21 59 e-post: christoffer.rosenblad@xvivoperfusion.com<\/a><\/p>\n<\/div>\n

\n

About Us<\/strong><\/p>\n\n

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.<\/a><\/p>\n<\/div>\n

\n

Attachments<\/strong><\/p>\n\n

XVIVO Perfusion\u2019s warrant program 2020\/2022<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

On 31 March 2020, the annual general meeting of XVIVO Perfusion AB (publ) (\u201cXVIVO\u201d) resolved to issue up to 408,000…<\/p>\n","protected":false},"template":"","class_list":["post-2824","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other"],"acf":[],"yoast_head":"\nXVIVO Perfusion\u2019s warrant program 2020\/2022 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusions-warrant-program-2020-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO Perfusion\u2019s warrant program 2020\/2022 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"On 31 March 2020, the annual general meeting of XVIVO Perfusion AB (publ) (\u201cXVIVO\u201d) resolved to issue up to 408,000...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusions-warrant-program-2020-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusions-warrant-program-2020-2022\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusions-warrant-program-2020-2022\\\/\",\"name\":\"XVIVO Perfusion\u2019s warrant program 2020\\\/2022 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2020-09-24T05:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusions-warrant-program-2020-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusions-warrant-program-2020-2022\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusions-warrant-program-2020-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO Perfusion\u2019s warrant program 2020\\\/2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO Perfusion\u2019s warrant program 2020\/2022 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusions-warrant-program-2020-2022\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO Perfusion\u2019s warrant program 2020\/2022 - XVIVO","og_description":"On 31 March 2020, the annual general meeting of XVIVO Perfusion AB (publ) (\u201cXVIVO\u201d) resolved to issue up to 408,000...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusions-warrant-program-2020-2022\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusions-warrant-program-2020-2022\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusions-warrant-program-2020-2022\/","name":"XVIVO Perfusion\u2019s warrant program 2020\/2022 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2020-09-24T05:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusions-warrant-program-2020-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusions-warrant-program-2020-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusions-warrant-program-2020-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO Perfusion\u2019s warrant program 2020\/2022"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2824","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2824"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}